终末期肾病及氢氧化铝对三唑仑药代动力学的影响。
Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
作者信息
Kroboth P D, Smith R B, Silver M R, Rault R, Sorkin M I, Puschett J B, Juhl R P
出版信息
Br J Clin Pharmacol. 1985 Jun;19(6):839-42. doi: 10.1111/j.1365-2125.1985.tb02725.x.
Triazolam 0.5 mg was administered to 11 dialysis patients and 11 age, weight and sex matched controls. Peak plasma concentrations (Cmax) were higher in control subjects, but there were no other differences between the groups. When dialysis patients took triazolam with 3600 mg aluminum hydroxide suspension, Cmax and AUC were increased into the range observed in control subjects. It appears that triazolam can be used at normal doses in patients with renal dysfunction, without regard to interaction with aluminum hydroxide gel, or to alterations in elimination.
给11名透析患者和11名年龄、体重及性别匹配的对照者服用了0.5毫克三唑仑。对照组受试者的血浆峰浓度（Cmax）较高，但两组之间没有其他差异。当透析患者服用三唑仑并同时服用3600毫克氢氧化铝混悬液时，Cmax和曲线下面积（AUC）增加到了对照组受试者观察到的范围内。看来肾功能不全患者可以使用正常剂量的三唑仑，无需考虑其与氢氧化铝凝胶的相互作用或消除的改变。
Zotero 插件